What is a stock summary page? Click here for an overview.
Business Description
BeiGene Ltd
NAICS : 541714
SIC : 2834
ISIN : KYG1146Y1017
Share Class Description:
STU:49B: Ordinary SharesCompare
Compare
Traded in other countries / regions
ONC.USA06160.Hong Kong688235.China49B.GermanyB1ME34.BrazilBGNE.Mexico IPO Date
2018-08-08Description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.43 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -2.72 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.98 | |||||
| Beneish M-Score | -2.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 41.9 | |||||
| 3-Year EBITDA Growth Rate | 36.9 | |||||
| 3-Year EPS without NRI Growth Rate | 27 | |||||
| 3-Year FCF Growth Rate | 28.5 | |||||
| 3-Year Book Growth Rate | -19.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 18.38 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.85 | |||||
| 9-Day RSI | 42.83 | |||||
| 14-Day RSI | 43.63 | |||||
| 3-1 Month Momentum % | 23.45 | |||||
| 6-1 Month Momentum % | 14.74 | |||||
| 12-1 Month Momentum % | 80.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | |||||
| Quick Ratio | 1.58 | |||||
| Cash Ratio | 1.19 | |||||
| Days Inventory | 274.43 | |||||
| Days Sales Outstanding | 49.2 | |||||
| Days Payable | 211.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | -1.47 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.41 | |||||
| Operating Margin % | -14.91 | |||||
| Net Margin % | -16.92 | |||||
| FCF Margin % | -17.53 | |||||
| ROE % | -18.93 | |||||
| ROA % | -11.14 | |||||
| ROIC % | -23.43 | |||||
| 3-Year ROIIC % | 57.57 | |||||
| ROC (Joel Greenblatt) % | -34.76 | |||||
| ROCE % | -14.9 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 367.39 | |||||
| PS Ratio | 6.45 | |||||
| PB Ratio | 7.44 | |||||
| Price-to-Tangible-Book | 7.73 | |||||
| EV-to-EBIT | -46.49 | |||||
| EV-to-Forward-EBIT | 207.99 | |||||
| EV-to-EBITDA | -66.63 | |||||
| EV-to-Forward-EBITDA | 109.26 | |||||
| EV-to-Revenue | 6.93 | |||||
| EV-to-Forward-Revenue | 5.17 | |||||
| EV-to-FCF | -39.44 | |||||
| Price-to-GF-Value | 0.53 | |||||
| Price-to-Net-Current-Asset-Value | 17.57 | |||||
| Price-to-Net-Cash | 538.83 | |||||
| Earnings Yield (Greenblatt) % | -2.15 | |||||
| FCF Yield % | -2.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BeiGene Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,534.228 | ||
| EPS (TTM) (€) | -0.445 | ||
| Beta | 1.59 | ||
| 3-Year Sharpe Ratio | 0.4 | ||
| 3-Year Sortino Ratio | 0.64 | ||
| Volatility % | 49.06 | ||
| 14-Day RSI | 43.63 | ||
| 14-Day ATR (€) | 0.634872 | ||
| 20-Day SMA (€) | 17.5195 | ||
| 12-1 Month Momentum % | 80.81 | ||
| 52-Week Range (€) | 8.95 - 20 | ||
| Shares Outstanding (Mil) | 1,400.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeiGene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeiGene Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BeiGene Ltd Frequently Asked Questions
What is BeiGene Ltd(STU:49B)'s stock price today?
The current price of STU:49B is €16.17. The 52 week high of STU:49B is €20.00 and 52 week low is €8.95.
When is next earnings date of BeiGene Ltd(STU:49B)?
The next earnings date of BeiGene Ltd(STU:49B) is 2025-05-08 Est..
Does BeiGene Ltd(STU:49B) pay dividends? If so, how much?
BeiGene Ltd(STU:49B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers